Industry: Information Technology Services

Sector: Technology

Clarivate Plc, an information, analytics, and workflow company, provides structured information and analytics for discovery, development, protection, commercialization, and measurement of scientific research, innovations, and brands. The company operates through three segments: Academia and Government, Life Sciences and Healthcare, and Intellectual Property. It offers Web of Science products and services, such as Web of Science, InCites, Journal Citation Reports, EndNote, ProQuest One, Pivot, Polaris, eBook Central, Vegs, Alma, ScholarOne, Converis, Publons, and Kopernio to organizations that plan, fund, implement, and utilize research; and Life Sciences products, including Cortellis products for pharmaceutical and biotechnology companies to support research, market intelligence, and competitive monitoring in connection with the development and commercialization of new drugs; and Real World Data, Dialog, Drug Safety Triager, and healthcare and data solutions. The company also provides Derwent products, which include Derwent Innovation, Innography, and IP Professional Services that enables its customers to evaluate the novelty of potential new products, confirm freedom to operate with respect to their product design, help them secure patent protection, assess the competitive technology landscape, and ensure that their products comply with required industry standards; and CompuMark products, such as trademark screening, searching, and watching products and services. It serves government and academic institutions, and life science and healthcare companies in the Americas, the Middle East, Africa, Europe, and the Asia Pacific. The company was formerly known as Clarivate Analytics Plc and changed its name to Clarivate Plc in May 2020. Clarivate Plc was founded in 1864 and is headquartered in London, the United Kingdom.

CLARIVATE Plc is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.